China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Up 102.2% in March

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 63,863 shares, an increase of 102.2% from the March 15th total of 31,586 shares. Based on an average daily volume of 116,894 shares, the short-interest ratio is currently 0.5 days. Approximately 6.9% of the shares of the stock are short sold.

Institutional Trading of China SXT Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC purchased a new stake in shares of China SXT Pharmaceuticals in the third quarter worth about $78,000. XTX Topco Ltd acquired a new stake in shares of China SXT Pharmaceuticals in the fourth quarter valued at about $36,000. Finally, Virtu Financial LLC raised its holdings in shares of China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after buying an additional 15,013 shares during the period. 5.02% of the stock is owned by hedge funds and other institutional investors.

China SXT Pharmaceuticals Stock Down 8.1%

SXTC stock traded down $0.19 during midday trading on Tuesday, hitting $2.13. The stock had a trading volume of 39,204 shares, compared to its average volume of 279,627. China SXT Pharmaceuticals has a 12-month low of $1.25 and a 12-month high of $1,046.98. The company’s 50-day moving average price is $2.17 and its 200 day moving average price is $119.06.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of China SXT Pharmaceuticals to a “sell” rating in a research note on Saturday, February 7th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.